Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering Xenon Pharmaceuticals (Nasdaq: XENE) priced an upsized underwritten public offering totaling 10,526,317 common shares and pre-funded warrants for 877,194 shares at $57.00 per common share (pre-funded warrants $56.9999), raising approximately $650.0 million in gross proceeds.The offering includes a 30-day underwriter option to buy up to 1,710,526 additional common shares and is expected to close on or about March 12, 2026. The securities were registered on a shelf registration filed August 9, 2024. No sales are being made in Canada.

#XENE Xenon Pharmaceuticals Announces Pricing of Upsized $650.0 Million Public Offering

www.stocktitan.net/news/XENE/xenon-pharmace...

Xenon Pharmaceuticals Announces Proposed Public Offering Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need,

#XENE Xenon Pharmaceuticals Announces Proposed Public Offering

www.stocktitan.net/news/XENE/xenon-pharmace...

Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS) Xenon (Nasdaq: XENE) reported positive topline Phase 3 X-TOLE2 results for azetukalner in focal onset seizures (FOS) on March 9, 2026. The trial met its primary endpoint with a -53.2% median percent change (MPC) in monthly FOS frequency for 25 mg versus -10.4% for placebo (placebo-adjusted -42.7%, p=6e-12).Key secondary RR50 was 54.8% (25 mg) versus 20.8% placebo. Safety was consistent with prior studies. Xenon plans to file an NDA in Q3 2026 and will present X-TOLE2 as a Late Breaking Science oral at AAN on April 19, 2026.

#XENE Xenon Announces Positive Topline Data from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures (FOS)

www.stocktitan.net/news/XENE/xenon-announce...

Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 Xenon Pharmaceuticals (Nasdaq: XENE) will announce topline results from the Phase 3 X-TOLE2 study of azetukalner in focal onset seizures on Monday, March 9, 2026. A live webcast and replay will be available via the company's Investors website; conference call details are provided.Conference call: 8:00 am ET (5:00 am PT) on March 9, 2026; dial-in and webcast registration information available.

#XENE Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026

www.stocktitan.net/news/XENE/xenon-to-annou...

Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update Xenon Pharmaceuticals (Nasdaq: XENE) reported Q4 and full-year 2025 results and a business update highlighting imminent clinical and cash milestones. X-TOLE2 Phase 3 topline data in focal onset seizures are expected in the first half of March 2026, with an anticipated NDA submission in H2 2026. Pro forma cash of $716.0M (including Q1 2026 ATM proceeds) supports operations into the second half of 2027. Multiple Phase 3 azetukalner studies continue to enroll; X-NOVA2 MDD topline data expected H1 2027. Early-stage Phase 1 data for XEN1701 and XEN1120 expected in 2026.

#XENE Xenon Reports Q4 and Full Year 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/XENE/xenon-reports-...

🚨 Institutions #optionsvolume surge detected! Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.

🚨 Institutions #optionsvolume surge detected!

Weekly Top Momentum Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #CRSR 303.8x
2. #QNCX 279.2x
3. #XENE 144.6x
4. #FTV 41.5x
5. #BWA 33.7x

#OptionFlow #OptionsTrading #Trading

Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference Xenon Pharmaceuticals (Nasdaq: XENE) outlined near-term clinical and regulatory milestones at the 2026 J.P. Morgan Healthcare Conference. Key timelines include X-TOLE2 topline data in March 2026 for azetukalner in focal onset seizures (380 patients randomized) and an anticipated NDA submission in H2 2026. Five additional placebo-controlled Phase 3 azetukalner studies remain active across epilepsy and neuropsychiatry, with X-NOVA2 topline data expected H1 2027 for major depressive disorder. Phase 1 SAD/MAD data for pain candidates XEN1701 (NaV1.7) and XEN1120 (KV7) are expected in 2026 to support Phase 2 proof-of-concept studies. The company also reported long-term OLE results showing sustained seizure reductions and detailed plans to support regulatory filings in multiple regions.

#XENE Xenon Outlines Key Upcoming Milestones at the 2026 J.P. Morgan Healthcare Conference

www.stocktitan.net/news/XENE/xenon-outlines...

グラン
#Xene
#InazumaEleven
#InazumaElevenFanart
#イナズマイレブン

Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025 Xenon (Nasdaq: XENE) presented interim 48-month open-label extension (X-TOLE OLE) data for azetukalner at AES 2025 showing durable seizure reductions and intervals of sustained seizure freedom. Among participants treated ≥48 months (n=131) the monthly median percent change in focal-onset seizure frequency improved from a 69.8% reduction at OLE month 1 to a 90.9% reduction at OLE month 48. Subgroup results showed a 100% monthly reduction for those on 1–2 ASMs (n=60) and 81.8% for those on 3 ASMs (n=69). Seizure freedom for ≥12, ≥24, ≥36, and ≥48 months was attained by 38.2%, 25.2%, 19.8%, and 10.7%, respectively. Analyses found many patients who experienced breakthrough seizures regained extended seizure-free epochs with continued treatment. Long-term safety was reported as comparable to the double-blind period. Additional real-world and preclinical Dravet data were also presented.

#XENE Xenon Showcases New 48-Month Azetukalner OLE Study Data in Epilepsy at AES 2025

www.stocktitan.net/news/XENE/xenon-showcase...

Xenon Reports Third Quarter 2025 Financial Results & Business Update Xenon Pharmaceuticals (Nasdaq: XENE) reported Q3 2025 results on Nov 3, 2025, and provided a business update focused on late‑stage development of azetukalner and early‑stage ion channel programs.Key points: Phase 3 X-TOLE2 completed randomization of 380 patients with topline data expected early 2026. X-NOVA2/X-NOVA3 (MDD) and X-CEED (BPD) continue to recruit. Phase 1 studies underway for XEN1701 (Nav1.7) and XEN1120 (Kv7). Cash, cash equivalents and marketable securities were $555.3M at Sept 30, 2025 with runway anticipated into 2027.

#XENE Xenon Reports Third Quarter 2025 Financial Results & Business Update

www.stocktitan.net/news/XENE/xenon-reports-...

Xenon Reports Second Quarter 2025 Financial Results & Business Update Xenon Pharmaceuticals (NASDAQ:XENE) reported Q2 2025 financial results and provided significant updates on its clinical programs. The company completed patient recruitment for its Phase 3 X-TOLE2 study of azetukalner, with topline data expected in early 2026. Xenon initiated Phase 3 trials for azetukalner in major depressive disorder (X-NOVA3) and bipolar depression (X-CEED).The company reported a net loss of $84.7 million for Q2 2025, compared to $57.9 million in Q2 2024. Cash position remained strong at $624.8 million, expected to fund operations into 2027. R&D expenses increased to $75.0 million, up from $49.7 million in the previous year, primarily due to ongoing clinical trials.Xenon strengthened its commercial readiness by appointing Darren Cline as Chief Commercial Officer to lead the anticipated azetukalner launch across multiple indications. The company also advanced its early-stage pipeline, initiating Phase 1 studies for both its Kv7 and Nav1.7 programs in pain treatment.

#XENE Xenon Reports Second Quarter 2025 Financial Results & Business Update

www.stocktitan.net/news/XENE/xenon-reports-...

Xenon Makes Major League Move: Dual Russell Index Inclusion Opens Door to $10.6T Investment Pool Neuroscience biotech Xenon joins both Russell indexes, marking major milestone. See how this dual inclusion impacts institutional investment exposure. Get details.

#XENE Xenon Joins the Russell 3000® and Russell 2000® Indexes

www.stocktitan.net/news/XENE/xenon-joins-th...

Xenon Reports First Quarter 2025 Financial Results and Provides Business Update Xenon Pharmaceuticals (XENE) reported Q1 2025 financial results and pipeline updates. The company's lead drug azetukalner is progressing in multiple Phase 3 trials. The X-TOLE2 focal onset seizures study is expected to complete recruitment soon, with topline data anticipated in early 2026. Two additional Phase 3 trials - X-NOVA3 for major depressive disorder (MDD) and a study for bipolar depression - are set to begin mid-year. The company initiated a Phase 1 study for XEN1120, a new Kv7 channel opener, and plans to file an IND for XEN1701, their Nav1.7 candidate, in Q3 2025. Financially, Xenon reported $691.1M in cash and equivalents as of March 31, 2025, with a net loss of $65.0M for Q1. Revenue was $7.5M, while R&D expenses increased to $61.2M. The company expects current cash to fund operations into 2027.

#XENE Xenon Reports First Quarter 2025 Financial Results and Provides Business Update

www.stocktitan.net/news/XENE/xenon-reports-...

Breakthrough Epilepsy Drug Shows Remarkable 3-Year Efficacy Data New long-term data reveals sustained seizure reduction and safety in 700+ patient-years study. Key findings showcase breakthrough potential in focal epilepsy treatment.

#XENE Xenon to Showcase Long-Term 36-Month Azetukalner Data at AAN 2025

www.stocktitan.net/news/XENE/xenon-to-showc...

Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update Xenon Pharmaceuticals (XENE) has provided its Q4 and full year 2024 financial results and business update. The company's lead drug candidate azetukalner is advancing in multiple Phase 3 trials, with topline data for focal onset seizures expected in H2 2025. The company is expanding its neuropsychiatric programs, with the first of three Phase 3 trials for major depressive disorder underway and plans to initiate bipolar depression studies mid-year.Financial highlights include: Cash position of $754.4 million as of December 31, 2024, expected to fund operations into 2027. R&D expenses increased to $210.4 million for 2024, up from $167.5 million in 2023. Net loss widened to $234.3 million in 2024 compared to $182.4 million in 2023.The company announced CFO Sherry Aulin will step down on June 30, 2025. Additionally, Xenon's collaboration with Neurocrine Biosciences achieved a milestone with the initiation of a Phase 1 study of their Nav1.2/Nav1.6 inhibitor, triggering a $7.5 million payment.

#XENE Xenon Reports Fourth Quarter & Full Year 2024 Financial Results and Business Update

www.stocktitan.net/news/XENE/xenon-reports-...

"More Fun", 2021, acrylic on paper, 14 x 11 inches. Collection of Elsie Worth, Denver.
#art #painting #abstraction #xene #johndoe

Xenon Pharmaceuticals Targets Major 2025 Milestone with Phase 3 Epilepsy Drug Data Xenon advances toward key azetukalner Phase 3 readout in H2 2025, backed by 600+ patient-years of safety data, while expanding into depression with new Phase 3 trials.

#XENE Xenon Outlines Key Corporate Milestone Opportunities for 2025

www.stocktitan.net/news/XENE/xenon-outlines...

Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024 | XENE Stock News Xenon Pharmaceuticals presented new long-term data from its X-TOLE open-label extension (OLE) study of azetukalner for focal onset seizures at AES 2024. Key findings show that approximately one-third of patients on azetukalner for at least 36 months achieved seizure freedom for a year or longer, with sustained monthly seizure frequency reductions maintained at 85% at month 36.The study demonstrated consistent tolerability and safety profile, with no new safety signals identified. Patient retention rates were 66%, 60%, and 52% at 12, 24, and 36 months respectively. Additional research presented highlighted significant mental health burdens in epilepsy patients and showed promising pre-clinical results for Nav1.1 potentiators in treating Dravet Syndrome.

#XENE Xenon Showcases New Long-Term Azetukalner Data from X-TOLE OLE Study in FOS at AES 2024

#investing #stocks #news

www.stocktitan.net/news/XENE/xenon-showcase...

#XENE Xenon to Showcase New Long-Term Azetukalner Data at AES 2024

www.stocktitan.net/news/XENE/xenon-to-showc...

#XENE Xenon to Present at Upcoming Investor Conferences

www.stocktitan.net/news/XENE/xenon-to-prese...